JP2024526305A5 - - Google Patents

Info

Publication number
JP2024526305A5
JP2024526305A5 JP2024500185A JP2024500185A JP2024526305A5 JP 2024526305 A5 JP2024526305 A5 JP 2024526305A5 JP 2024500185 A JP2024500185 A JP 2024500185A JP 2024500185 A JP2024500185 A JP 2024500185A JP 2024526305 A5 JP2024526305 A5 JP 2024526305A5
Authority
JP
Japan
Prior art keywords
represented
following
pharmaceutically acceptable
stereoisomer
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024526305A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/073517 external-priority patent/WO2023283606A1/en
Publication of JP2024526305A publication Critical patent/JP2024526305A/ja
Publication of JP2024526305A5 publication Critical patent/JP2024526305A5/ja
Pending legal-status Critical Current

Links

JP2024500185A 2021-07-08 2022-07-07 Lrrk2の野生型および変異体形態の分解剤ならびにその使用 Pending JP2024526305A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163219629P 2021-07-08 2021-07-08
US63/219,629 2021-07-08
PCT/US2022/073517 WO2023283606A1 (en) 2021-07-08 2022-07-07 Degraders of wild-type and mutant forms of lrrk2 and uses thereof

Publications (2)

Publication Number Publication Date
JP2024526305A JP2024526305A (ja) 2024-07-17
JP2024526305A5 true JP2024526305A5 (cg-RX-API-DMAC7.html) 2025-07-14

Family

ID=84802076

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500185A Pending JP2024526305A (ja) 2021-07-08 2022-07-07 Lrrk2の野生型および変異体形態の分解剤ならびにその使用

Country Status (6)

Country Link
US (1) US20240308982A1 (cg-RX-API-DMAC7.html)
EP (1) EP4367115A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024526305A (cg-RX-API-DMAC7.html)
AU (1) AU2022306049A1 (cg-RX-API-DMAC7.html)
CA (1) CA3218951A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023283606A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3211347A1 (en) 2021-03-19 2022-09-22 Erika Araujo Indazole based compounds and associated methods of use
AU2024352092A1 (en) 2023-09-28 2026-04-09 Arvinas Operations, Inc. Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (lrrk2)
WO2025201511A1 (zh) * 2024-03-29 2025-10-02 上海京新生物医药有限公司 吲唑衍生物及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014134772A1 (en) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
US20210361774A1 (en) * 2018-10-16 2021-11-25 Dana-Farber Cancer Institute, Inc. Degraders of wild-type and mutant forms of lrrk2

Similar Documents

Publication Publication Date Title
JP7836788B2 (ja) 新規なカルボニル脂質、および核酸を送達するための脂質ナノ粒子製剤
JP2018518537A5 (cg-RX-API-DMAC7.html)
JP2022505234A5 (cg-RX-API-DMAC7.html)
JP2008508360A5 (cg-RX-API-DMAC7.html)
JP2022533069A5 (cg-RX-API-DMAC7.html)
JP2019504899A5 (cg-RX-API-DMAC7.html)
US20130190327A1 (en) Bis-fatty acid conjugates and their uses
JP2024542188A5 (cg-RX-API-DMAC7.html)
JP2010509366A5 (cg-RX-API-DMAC7.html)
JP2017088633A5 (cg-RX-API-DMAC7.html)
JP2010507585A5 (cg-RX-API-DMAC7.html)
JP2008512490A5 (cg-RX-API-DMAC7.html)
JP2015508068A5 (cg-RX-API-DMAC7.html)
JP5290773B2 (ja) 造影剤
JP2013531634A (ja) オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
JP2012525393A5 (cg-RX-API-DMAC7.html)
JP2009530399A5 (cg-RX-API-DMAC7.html)
JP2014500861A5 (cg-RX-API-DMAC7.html)
JP2010511626A5 (cg-RX-API-DMAC7.html)
JP2017536395A5 (cg-RX-API-DMAC7.html)
JP2012528858A5 (cg-RX-API-DMAC7.html)
JP2010524965A5 (cg-RX-API-DMAC7.html)
JP2009541224A5 (cg-RX-API-DMAC7.html)
JP2014505017A5 (cg-RX-API-DMAC7.html)
JP2007505044A5 (cg-RX-API-DMAC7.html)